[{"id":"2304e211-cb24-49e4-804c-c1f372c07411","acronym":"ARTEMIDE-HCC01","url":"https://clinicaltrials.gov/study/NCT06921785","created_at":"2025-06-07T14:44:45.235Z","updated_at":"2025-06-07T14:44:45.235Z","phase":"Phase 3","brief_title":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","source_id_and_acronym":"NCT06921785 - ARTEMIDE-HCC01","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imjudo (tremelimumab-actl) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 1220","initiation":"Initiation: 05/06/2025","start_date":" 05/06/2025","primary_txt":" Primary completion: 03/16/2029","primary_completion_date":" 03/16/2029","study_txt":" Completion: 03/15/2030","study_completion_date":" 03/15/2030","last_update_posted":"2025-05-31"},{"id":"008c4fb4-f4aa-40c4-a175-3806ddd34919","acronym":"ARTEMIDELung04","url":"https://clinicaltrials.gov/study/NCT06868277","created_at":"2025-06-07T15:03:08.757Z","updated_at":"2025-06-07T15:03:08.757Z","phase":"Phase 3","brief_title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT06868277 - ARTEMIDELung04","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 830","initiation":"Initiation: 04/10/2025","start_date":" 04/10/2025","primary_txt":" Primary completion: 01/17/2030","primary_completion_date":" 01/17/2030","study_txt":" Completion: 12/02/2030","study_completion_date":" 12/02/2030","last_update_posted":"2025-05-14"},{"id":"a672992d-19fb-49b7-9557-516b222cb23a","acronym":"ARTEMIDE-Lung03","url":"https://clinicaltrials.gov/study/NCT06627647","created_at":"2025-02-25T13:36:39.041Z","updated_at":"2025-02-25T13:36:39.041Z","phase":"Phase 3","brief_title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC","source_id_and_acronym":"NCT06627647 - ARTEMIDE-Lung03","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 878","initiation":"Initiation: 11/27/2024","start_date":" 11/27/2024","primary_txt":" Primary completion: 05/10/2029","primary_completion_date":" 05/10/2029","study_txt":" Completion: 03/25/2030","study_completion_date":" 03/25/2030","last_update_posted":"2025-02-21"},{"id":"57bae4b0-28a5-4fa9-adc4-a7b4d7841588","acronym":"NeoCOAST-2","url":"https://clinicaltrials.gov/study/NCT05061550","created_at":"2021-09-29T11:53:57.404Z","updated_at":"2025-02-25T15:12:20.063Z","phase":"Phase 2","brief_title":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05061550 - NeoCOAST-2","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • oleclumab (MEDI9447) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • falbikitug (AZD0171) • monalizumab (IPH2201)"],"overall_status":"Recruiting","enrollment":" Enrollment 630","initiation":"Initiation: 04/14/2022","start_date":" 04/14/2022","primary_txt":" Primary completion: 05/09/2030","primary_completion_date":" 05/09/2030","study_txt":" Completion: 05/09/2030","study_completion_date":" 05/09/2030","last_update_posted":"2025-02-13"},{"id":"9d25a695-254b-48a3-8558-1b24c9498777","acronym":"ARTEMIDE-01","url":"https://clinicaltrials.gov/study/NCT04995523","created_at":"2021-08-09T14:53:19.305Z","updated_at":"2025-02-25T15:12:13.323Z","phase":"Phase 1/2","brief_title":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","source_id_and_acronym":"NCT04995523 - ARTEMIDE-01","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 199","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 08/18/2026","primary_completion_date":" 08/18/2026","study_txt":" Completion: 03/16/2028","study_completion_date":" 03/16/2028","last_update_posted":"2025-02-13"},{"id":"c806a099-ac30-4f24-bc10-a04a25d2bf23","acronym":"GEMINI-Gastric","url":"https://clinicaltrials.gov/study/NCT05702229","created_at":"2023-11-09T18:13:01.598Z","updated_at":"2025-02-25T15:13:18.164Z","phase":"Phase 2","brief_title":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT05702229 - GEMINI-Gastric","lead_sponsor":"AstraZeneca","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 01/16/2023","start_date":" 01/16/2023","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/28/2027","study_completion_date":" 01/28/2027","last_update_posted":"2025-02-13"},{"id":"e4341e18-0636-4930-ba0b-0c9da6c26d3f","acronym":"DESTINY-BTC01","url":"https://clinicaltrials.gov/study/NCT06467357","created_at":"2025-02-25T15:45:41.147Z","updated_at":"2025-02-25T15:45:41.147Z","phase":"Phase 3","brief_title":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","source_id_and_acronym":"NCT06467357 - DESTINY-BTC01","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 620","initiation":"Initiation: 08/12/2024","start_date":" 08/12/2024","primary_txt":" Primary completion: 06/12/2028","primary_completion_date":" 06/12/2028","study_txt":" Completion: 05/16/2029","study_completion_date":" 05/16/2029","last_update_posted":"2025-02-11"},{"id":"95c0229a-8b91-4b07-bbd8-e69278f6a209","acronym":"DESTINY-Gastric03","url":"https://clinicaltrials.gov/study/NCT04379596","created_at":"2021-01-18T21:09:02.628Z","updated_at":"2025-02-25T16:32:08.037Z","phase":"Phase 2","brief_title":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","source_id_and_acronym":"NCT04379596 - DESTINY-Gastric03","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • Imfinzi (durvalumab) • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • rilvegostomig (AZD2936) • volrustomig (MEDI5752)"],"overall_status":"Recruiting","enrollment":" Enrollment 413","initiation":"Initiation: 06/03/2020","start_date":" 06/03/2020","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2025-02-07"},{"id":"469953ef-24ff-4f0d-8592-38f0c64f71f3","acronym":"TROPION-Lung04","url":"https://clinicaltrials.gov/study/NCT04612751","created_at":"2021-01-19T20:32:55.031Z","updated_at":"2025-02-25T16:45:13.114Z","phase":"Phase 1","brief_title":"Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04612751 - TROPION-Lung04","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 371","initiation":"Initiation: 02/02/2021","start_date":" 02/02/2021","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-05"},{"id":"6cdcc31a-0ce3-49ee-bdf9-1051ddeebebe","acronym":"TROPION-Lung10","url":"https://clinicaltrials.gov/study/NCT06357533","created_at":"2024-04-10T18:42:49.173Z","updated_at":"2025-02-25T16:55:47.733Z","phase":"Phase 3","brief_title":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations","source_id_and_acronym":"NCT06357533 - TROPION-Lung10","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1 • TACSTD2","pipe":" | ","alterations":" TROP2 positive","tags":["PD-L1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TROP2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 675","initiation":"Initiation: 04/11/2024","start_date":" 04/11/2024","primary_txt":" Primary completion: 04/24/2028","primary_completion_date":" 04/24/2028","study_txt":" Completion: 05/24/2030","study_completion_date":" 05/24/2030","last_update_posted":"2025-02-04"},{"id":"22c9a347-6084-448c-8e14-d13087fa8660","acronym":"MST01-AZN-05","url":"https://clinicaltrials.gov/study/NCT06366451","created_at":"2025-02-25T15:09:09.368Z","updated_at":"2025-02-25T15:09:09.368Z","phase":"Phase 1","brief_title":"PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC","source_id_and_acronym":"NCT06366451 - MST01-AZN-05","lead_sponsor":"Presage Biosciences","biomarkers":" TMB • MSI","pipe":"","alterations":" ","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • tilatamig samrotecan (AZD9592) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 05/22/2024","start_date":" 05/22/2024","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-01-20"},{"id":"e1db77e0-90c7-4f64-afe7-e9f653e16ebf","acronym":"ARTEMIDE-Gastric01","url":"https://clinicaltrials.gov/study/NCT06764875","created_at":"2025-02-26T07:06:51.440Z","updated_at":"2025-02-26T07:06:51.440Z","phase":"Phase 3","brief_title":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","source_id_and_acronym":"NCT06764875 - ARTEMIDE-Gastric01","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • rilvegostomig (AZD2936)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 840","initiation":"Initiation: 03/28/2025","start_date":" 03/28/2025","primary_txt":" Primary completion: 04/27/2029","primary_completion_date":" 04/27/2029","study_txt":" Completion: 12/09/2030","study_completion_date":" 12/09/2030","last_update_posted":"2025-01-09"},{"id":"b5c67bd8-1ff6-480e-a8fd-8f1eefdac24b","acronym":"ARTEMIDE-Lung02","url":"https://clinicaltrials.gov/study/NCT06692738","created_at":"2025-02-26T08:58:21.285Z","updated_at":"2025-02-26T08:58:21.285Z","phase":"Phase 3","brief_title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT06692738 - ARTEMIDE-Lung02","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 880","initiation":"Initiation: 11/18/2024","start_date":" 11/18/2024","primary_txt":" Primary completion: 02/05/2029","primary_completion_date":" 02/05/2029","study_txt":" Completion: 10/08/2029","study_completion_date":" 10/08/2029","last_update_posted":"2024-12-11"},{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"39769fed-659c-4bfe-8a22-cc44cf784049","acronym":"","url":"https://clinicaltrials.gov/study/NCT04541108","created_at":"2021-01-18T21:43:38.590Z","updated_at":"2024-07-02T16:35:08.887Z","phase":"Phase 1","brief_title":"Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies","source_id_and_acronym":"NCT04541108","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • BMS-986299 • MK-0482 • MK-4830 • dazostinag (TAK-676) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/26/2021","start_date":" 07/26/2021","primary_txt":" Primary completion: 12/01/2031","primary_completion_date":" 12/01/2031","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-04-18"},{"id":"b10fda2b-447e-4f1a-a80d-b097d7fb22c5","acronym":"MAGELLAN","url":"https://clinicaltrials.gov/study/NCT03819465","created_at":"2021-01-18T18:52:14.035Z","updated_at":"2024-07-02T16:35:17.376Z","phase":"Phase 1","brief_title":"A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC","source_id_and_acronym":"NCT03819465 - MAGELLAN","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" EGFR mutation • ALK fusion","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • oleclumab (MEDI9447) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • danvatirsen (AZD9150)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 175","initiation":"Initiation: 12/27/2018","start_date":" 12/27/2018","primary_txt":" Primary completion: 05/23/2023","primary_completion_date":" 05/23/2023","study_txt":" Completion: 03/26/2026","study_completion_date":" 03/26/2026","last_update_posted":"2024-02-28"},{"id":"ec6b4d27-2469-4ce6-b4e8-f4802bcd39f5","acronym":"MERIDIAN","url":"https://clinicaltrials.gov/study/NCT05414032","created_at":"2023-07-03T19:09:41.337Z","updated_at":"2025-02-25T15:00:27.315Z","phase":"Phase 2","brief_title":"Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC","source_id_and_acronym":"NCT05414032 - MERIDIAN","lead_sponsor":"University Health Network, Toronto","biomarkers":" PD-L1 • TIGIT","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TIGIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/12/2023","start_date":" 07/12/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-10-25"}]